Company Number: 13527839

Analysis Date: 2025-07-20 12:12 UTC

1. Credit Opinion: CONDITIONAL APPROVAL
   Biomonde Limited is a micro-entity with a relatively short trading history (incorporated in 2021) and no fixed assets. The company shows a significant decline in net current assets from £1.27M in 2023 to £245k in 2024, mainly due to increased current liabilities and reduced current assets. This deterioration raises concerns about liquidity and operational cash flow management. However, the company remains solvent with positive net assets of £245k and no long-term debt. The business operates in a niche medical sector (larval therapy), suggesting potential for growth but also exposure to market and regulatory risks. Approval is conditional on closer monitoring of liquidity and trade performance, and requiring updated financial forecasts.

2. Financial Strength:

• Net assets decreased by approximately 47% from £462k in 2023 to £245k in 2024, indicating a weakening balance sheet.
• Current assets have fallen by about 32% to £1.07M, while current liabilities increased sharply from £303k in 2023 to £825k in 2024, reflecting possible short-term funding pressures.
• No fixed assets or capital employed in long-term investments; the company relies heavily on current assets and working capital for operations.
• Share capital is nominal (£120), indicating limited equity injection.
• Absence of long-term creditors in 2024 suggests reliance on short-term financing.

3. Cash Flow Assessment:

• The net current assets position remains positive but sharply reduced, suggesting tighter liquidity.
• No employees on record, which may imply outsourcing or a business model focused on holding or IP licensing rather than active operations.
• The increase in current liabilities may be trade creditors or accrued expenses; a detailed cash flow statement would be needed to confirm operating cash generation.
• Given the reduction in working capital, the company’s ability to meet short-term obligations could be strained without additional funding or improved receivables collection.

4. Monitoring Points:

• Watch quarterly cash flow and bank balances to ensure liquidity remains adequate to cover rising current liabilities.
• Monitor trade creditor aging and payment patterns to avoid supplier strain.
• Track any new capital injections or financing arrangements to bolster equity or working capital.
• Review business development progress in the larval therapy market to assess revenue growth prospects.
• Keep an eye on director changes and governance, particularly as a new director was appointed recently, which may impact strategic direction.